heme pharm Flashcards Preview

Step 1 - Pharm > heme pharm > Flashcards

Flashcards in heme pharm Deck (30)
Loading flashcards...
1
Q

MOA of Heperin

A

cofactor for activation of antithrombin. reduces thrombin and factor xa

2
Q

use of heparin

A

immediate antocoag for PE, acute coronary syndrome, MI, DVT

3
Q

anticoag safe in pregnancy

A

heparin

4
Q

antidote for heparin OD

A

protamine sulfate

5
Q

type of heparin not easily reversable

A

low molecular weight

6
Q

reaction to heparin that can cause thombosis and thrombocytopenia

A

HIT - development of IgG antibodies against heparin, forms antibody complex that actiavtes platelets leading to thombosis

7
Q

used as alternative to heparin in HIT

A

lepirudin, bivalirudin

8
Q

MOA of warfarin

A

interferes with synth and activation of vit K dependant clotting factors

9
Q

clinical effect of warfarin

A

effects extrinsic pathway, increasing PT

10
Q

use of warfarin

A

chronic anticoag (post STEMI, venous thromboembolism prophalaxis, prevention of stroke in Afib)

11
Q

ongoing tests for warfarin use

A

PT/INR values

12
Q

tox of warfarin

A

bleeding, birth defects, skin/tissue necrosis, drug-drug interaction

13
Q

drug that interferes with damn near everything

A

warfarin

14
Q

reversal of warfarin

A

vit K (fresh frozen plasma if severe)

15
Q

site of action of heparin/warfarin

A

blood/liver

16
Q

onset time of heparin/warfarin

A

rapid/slow

17
Q

lab value heparin affects

A

PTT (intrinsic)

18
Q

MOA of tPA

A

aids conversion of plasminogen to plasmin (cleaves thrombin and fibrin clots)

19
Q

lab value tPA affects

A

PT, PTT

20
Q

treat tox of tPA with

A

aminocaproic acid

21
Q

MOA of asprin

A

irreversable inhibits COX-1/2 enxyme

22
Q

lab effect of aspirin

A

bleeding time increase

23
Q

proteins asprin inhibits

A

TXA2 and prostaglandins

24
Q

tox of aspirin

A

ulcers, tinntus,

25
Q

OD of asprin casues

A

resp alk, and metabolic acid

26
Q

MOA of clopidogrel/ticlopidine

A

inhibts platelet aggregation by irriversablly binding ADP receptors. Inhibits fibrogen binding by preventing IIb/IIIa from binding to fibrinogen

27
Q

use of clopidogrel/ticlopidine

A

ACS, coronary stenting, prevent reccurence/incidence of thrombotic stroke

28
Q

tox of clopidogrel/ticlopidine

A

neutropenia

29
Q

MAO of cliostazol/dipyridamole

A

inhibits phosphpdiesterate III, increases cAMP, inhibits platelet aggregation. Also vasodilator

30
Q

use of cliostazol/dipyridamole

A

ACS, PCI